PURPOSE: Since many drug targets and metabolizing enzymes are developmentally regulated, we investigated a potential comparable regulation of inosine 5'-monophosphate dehydrogenase (IMPDH) activity that has recently been advocated as a pharmacodynamic biomarker of mycophenolic acid (MPA) effects in the paediatric population. Since the field of pharmacodynamic monitoring of MPA is evolving, we also analyzed the response of IMPDH activity on MPA in children vs adolescents after renal transplantation. METHODS: We analyzed IMPDH activity in peripheral blood mononuclear cells (PBMCs) in 79 healthy children aged 2.0-17.9 years in comparison to 106 healthy adults. Pharmacokinetic/pharmacodynamic profiles of MPA and IMPDH over 6 or 12 h after mycophenolate mofetil dosing were performed in 17 paediatric renal transplant recipients. IMPDH activity was measured by HPLC and normalized to the adenosine monophosphate (AMP) content of the cells, MPA plasma concentrations were measured by HPLC. RESULTS: Inosine 5'-monophosphate dehydrogenase activity displayed a high inter-individual variability (coefficient of variation 40.2%) throughout the entire age range studied. Median IMPDH did not differ significantly in healthy pre-school children (82 [range, 42-184] μmol/s/mol AMP), school-age children (61 [30-153]), adolescents (83 [43-154]) and healthy adults (83 [26-215]). Similar to adults, IMPDH activity in children and adolescents was inversely correlated with MPA plasma concentration. CONCLUSIONS: In conclusion, our data do not show a pronounced developmental regulation of IMPDH activity in PBMCs in the paediatric population and there is a comparable inhibition of IMPDH activity by MPA in children and adolescents after renal transplantation.
PURPOSE: Since many drug targets and metabolizing enzymes are developmentally regulated, we investigated a potential comparable regulation of inosine 5'-monophosphate dehydrogenase (IMPDH) activity that has recently been advocated as a pharmacodynamic biomarker of mycophenolic acid (MPA) effects in the paediatric population. Since the field of pharmacodynamic monitoring of MPA is evolving, we also analyzed the response of IMPDH activity on MPA in children vs adolescents after renal transplantation. METHODS: We analyzed IMPDH activity in peripheral blood mononuclear cells (PBMCs) in 79 healthy children aged 2.0-17.9 years in comparison to 106 healthy adults. Pharmacokinetic/pharmacodynamic profiles of MPA and IMPDH over 6 or 12 h after mycophenolate mofetil dosing were performed in 17 paediatric renal transplant recipients. IMPDH activity was measured by HPLC and normalized to the adenosine monophosphate (AMP) content of the cells, MPA plasma concentrations were measured by HPLC. RESULTS: Inosine 5'-monophosphate dehydrogenase activity displayed a high inter-individual variability (coefficient of variation 40.2%) throughout the entire age range studied. Median IMPDH did not differ significantly in healthy pre-school children (82 [range, 42-184] μmol/s/mol AMP), school-age children (61 [30-153]), adolescents (83 [43-154]) and healthy adults (83 [26-215]). Similar to adults, IMPDH activity in children and adolescents was inversely correlated with MPA plasma concentration. CONCLUSIONS: In conclusion, our data do not show a pronounced developmental regulation of IMPDH activity in PBMCs in the paediatric population and there is a comparable inhibition of IMPDH activity by MPA in children and adolescents after renal transplantation.
Authors: K Budde; P Glander; K P Braun; T Böhler; J Waiser; L Fritsche; I Mai; H Neumayer Journal: Transplant Proc Date: 2001 Nov-Dec Impact factor: 1.066
Authors: H Takahashi; S Ishikawa; S Nomoto; Y Nishigaki; F Ando; T Kashima; S Kimura; M Kanamori; H Echizen Journal: Clin Pharmacol Ther Date: 2000-11 Impact factor: 6.875
Authors: Klemens Budde; Petra Glander; Bernhard K Krämer; Wolfgang Fischer; Ute Hoffmann; Steffen Bauer; Jana Grohmann; Hans-Hellmut Neumayer; Wolfgang Arns Journal: Transplantation Date: 2007-02-27 Impact factor: 4.939
Authors: L T Weber; T Lamersdorf; M Shipkova; P D Niedmann; M Wiesel; L B Zimmerhackl; A Staskewitz; E Schütz; O Mehls; M Oellerich; V W Armstrong; B Tönshoff Journal: Ther Drug Monit Date: 1999-10 Impact factor: 3.681
Authors: Ferdi Sombogaard; Ron H N van Schaik; Ron A Mathot; Klemens Budde; Marloes van der Werf; Arnold G Vulto; Willem Weimar; Petra Glander; Laurent Essioux; Teun van Gelder Journal: Pharmacogenet Genomics Date: 2009-08 Impact factor: 2.089
Authors: Zaipul I Md Dom; Janet K Coller; Robert P Carroll; Jonathan Tuke; Brett C McWhinney; Andrew A Somogyi; Benedetta C Sallustio Journal: Br J Clin Pharmacol Date: 2018-08-07 Impact factor: 4.335
Authors: Jiang-Tao Tang; Brenda C de Winter; Dennis A Hesselink; Ferdi Sombogaard; Lan-Lan Wang; Teun van Gelder Journal: Br J Clin Pharmacol Date: 2016-11-30 Impact factor: 4.335
Authors: Min Dong; Tsuyoshi Fukuda; Shareen Cox; Marij T de Vries; David K Hooper; Jens Goebel; Alexander A Vinks Journal: Br J Clin Pharmacol Date: 2014-11 Impact factor: 4.335